CD274 and gastric cancer: The CheckMate 649 study explored the survival of patients with different response levels in the field of first-line immunotherapy for gastric cancer and revealed that Chinese patients (PD-L1 CPS ≥5) who achieved CR or PR at 18 weeks with nivolumab combined with chemotherapy had a 3-year OS rate of 37% and an mOS of 21.5 months (42).